Imeglimin, a novel antidiabetic agent related to metformin, attenuates knee osteoarthritis development and progression through AMPK activation and NF-κB signaling inhibition.

Yuki Hyodo, Yukio Akasaki, Ichiro Kurakazu, Masanari Kuwahara, Taisuke Uchida, Ryota Hirose, Mamiko Sakai, Takumi Kita, Koki Kato, Yasuharu Nakashima

Department of Orthopaedic Surgery, Kyushu University, Fukuoka, Japan. Electronic address: [email protected]. · pubmed

Paper

Abstract

Metformin, a first-line treatment for type 2 diabetes, attenuates hallmarks of aging and protects against age-related diseases, including osteoarthritis (OA). Here, we assessed the effects of imeglimin, a novel antidiabetic agent related to metformin, on the development and progression of knee OA.

The following analysis is generated by AI and may contain errors. It is separate from the authors’ abstract and is not peer review.

Research summary

Imeglimin attenuates knee osteoarthritis development and progression through AMPK activation and NF-κB signaling inhibition. The paper is relevant as it explores a novel antidiabetic agent that may influence mechanisms related to aging and age-related diseases, specifically osteoarthritis, which is linked to the aging process.

Author of this paper? Send a correction.